New hope for Hard-to-Treat cervical cancer? drug trial targets HER2
NCT ID NCT07051486
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a drug called SHR-A1811 in 60 women with HER2-expressing cervical cancer that has spread or returned after standard treatments. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A1811 (an antibody-drug conjugate targeting HER2)
What this could lead to
If successful, this could offer a new treatment option for people with HER2-positive cervical cancer that has not responded to standard therapies.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors in many patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shandong University Qilu Hospital
RECRUITINGJinan, Shandong, 250063, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact